EVRY, France--(BUSINESS WIRE)--Atamyo Therapeutics a clinical-stage biotechnology company focused on the development of new generation gene therapies targeting muscular dystrophies and ...
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major ...
India, April 5 -- Myotonic dystrophy type 1 (DM1) is the leading form of muscular dystrophy that appears in adulthood. While it is best known for causing progressive muscle weakness and loss, the ...
Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire Kate Therapeutics, according to the Big Pharma’s CEO. The Swiss drugmaker ...
University of Manchester scientists have mapped the mutations in the tiny protein chains that cause a subtype of muscular dystrophy. Published in the journal Nature Communications, the study provides ...
Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function. Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results